Fig. 3: Therapeutic effects of neoadjuvant agonist combination on tumor growth and survival.
a, Mice bearing different tumor types were treated with STING agonist ADU-S100 (2 μg intratumoral) and/or anti-LTβR agonistic antibody (100 μg, i.p.) as indicated (arrowheads), and the tumor growth curves were monitored until surgical resection. s.c., subcutaneous. N = 22–28 (KPC), N = 11–18 (Py230), N = 5 (76-9) tumors from 2 independent experiments combined, representing biological replicates. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. b, Subcutaneous KPC tumor growth in wild-type (WT) or T cell-deficient nude mice treated or untreated with combination therapy. N = 10 or 12. c, CD4+ T cells and/or CD8+ T cells are depleted in combination therapy-treated and untreated mice by i.p. injection of depletion antibodies one or two days before KPC tumor inoculation (s.c.) as described in Extended Data Fig. 3a. Isotype IgG was injected to the no-depletion control group. Tumor growth was monitored for 14 days. N = 10. d, Subcutaneous KPC tumor growth in WT or B cell-deficient CD79a knockout mice treated or untreated with combination therapy. N = 20. e, Treatment schedule of neoadjuvant agonist therapies for s.c. KPC tumors and tumor resection followed by tumor reinoculation. The primary tumors were either TLS-rich or TLS-free at the time of the resection, depending on the neoadjuvant treatment options. f, Survival curves after tumor reinoculation. Sham control mice had no primary tumors but received tumor inoculation for the first time 2 weeks after sham surgery. N = 18–23. g, Growth curves of reinoculated tumors. For a–g, the results of two or more independent experiments were combined and presented in the graphs. Data in a–d are presented as the mean ± s.e.m. and analyzed using two-way ANOVA with Tukey’s test for statistical significance. All replicates represent biological replicates.
